ATTD-ASIA 2026 alongside Eli Lilly and Company are proud to present the second edition of the ATTD-ASIA 2026 Clinical Innovation Award.
This award will acknowledge significant contributions to improving the clinical practice of type 2 diabetes management. The ATTD-ASIA 2026 Clinical Innovation Award will emphasize practical improvements in day-to-day patient care. The focus will be on recognizing initiatives that directly enhance patient outcomes in clinical settings, particularly for type 2 diabetes patients.
The award will comprise of both financial and travel assistance to support the work of the winner and enable them to attend ATTD-ASIA 2026 in Kyoto, Japan.
Key Dates
- Submissions close: 30 August 2026
- Shortlisting: Mid-September 2026
- Winner informed: October 2026
- Award at ATTD-ASIA 2026: 9-11 December 2026
Eligibility
- Open to HCPs, researchers, or digital health innovators.
- Candidates should exhibit innovative, patient-centered approaches and
a commitment to translating research into practical solutions that can be scaled globally.
Criteria for Selection
- Patient-Centered Innovation: Practical, patient-focused interventions that enhance diabetes care.
- Clinical Impact: Demonstrated improvement in clinical outcomes, such as HbA1c, treatment adherence, and quality of life.
- Sustainability & Scalability: Solutions with potential for widespread adoption and lasting impact across healthcare systems.
- Evidence & Merit: Backed by strong research, pilot studies, or real-world data demonstrating effectiveness in improving patient care.
- Alignment with ATTD’s Vision: Reflects ATTD’s focus on advancing diabetes technology.
Note: If you’re applying for the ATTD-ASIA Clinical Innovation Award, we encourage you to register early or plan your trip in advance. The winner will be expected to attend the award ceremony in person and receive their award on stage during the event. Ensure you’re ready to be part of this exciting moment!
ATTD-ASIA 2025 Clinical Innovation Award Winner:
Dr. Amit Gupta
Recognized for pioneering AI-powered digital therapeutics in type 2 diabetes care.
